Work

PI3K/mTOR and topoisomerase inhibitors with potential activity against SARS-CoV-2 infection

Year: 2020

Type: preprint

Abstract: There is an urgent need to identify therapies to prevent and treat SARS-CoV-2 infection. We performed a statistical evaluation of in vitro gene expression profiles reflecting exposure to 1,835 drugs, and found topoisomerase inhibitors and PI3K/mTOR pathway inhibitors among the strongest candidates for reduced expression of ACE2, a host gene associated with SARS-CoV-2 infection. Retrospective clinical data suggest that patients on these agents may be less likely to test positive for SARS-CoV-2.

Source: medRxiv

DOI: 10.1101/2020.09.02.20186783

Authors: James Robert White, Michael Bonner Foote, Justin Jee, Guillem Argilés, Jonathan C.M. Wan, Luis Alberto Diaz

Institutions: Resphera Biosciences, Memorial Sloan Kettering Cancer Center

Language: English

Topic: SARS-CoV-2 and COVID-19 Research

Subfield: Infectious Diseases

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: green

Funders: American Association for Cancer Research, Entertainment Industry Foundation, National Institutes of Health, Stand Up To Cancer